Key statistics
On Friday, Esperion Therapeutics Inc (0ET:FRA) closed at 2.61, -25.57% below its 52-week high of 3.50, set on Jan 09, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.61 |
|---|---|
| High | 2.61 |
| Low | 2.61 |
| Bid | 2.86 |
| Offer | 2.95 |
| Previous close | 2.86 |
| Average volume | 4.40k |
|---|---|
| Shares outstanding | 239.06m |
| Free float | 237.60m |
| P/E (TTM) | -- |
| Market cap | 812.82m USD |
| EPS (TTM) | -0.5358 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 07:11 GMT.
More ▼
- Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
- Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
- Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
- Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
- Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
- Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
More ▼
